Google
CTNM — CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK (Healthcare >> Biotechnology)
CTNM FAQ
What is CTNM's ROE?
CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK reports a Return on Equity (ROE) of -23.37%.
What is CTNM's dividend yield?
CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK offers a dividend yield of 0.00%.
What is CTNM's Deepscope Quality Score?
Deepscope rates CTNM's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CTNM?
Deepscope's AI Timing Score for CTNM is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CTNM belong to?
CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 11.53
Price
0.04
(0.35%)
Day Change
|
|
|---|
CTNM, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 11.53 |
| PBV / Sector |
1.72 / 4.75
|
| Earning Per Share | -1.57 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
2.25 M
GREAT
|
| Average 1W Daily Value |
3.14 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-09 09:39:26 |
| Symbol | CTNM |
| Name | CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 32.72 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 429.57 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3565 General Atomics Court, San Diego, CA, United States, 92121
Phone: 858 333 5280
Website: https://www.contineum-tx.com
Employees: 51
Sector: Healthcare >> Biotechnology
Description: Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
